


CURRICULUM VITAE

Professeur David SAADOUN, MD PhD

Paris le 03.06.2024



ADDRESS Dept of Internal Medicine and Clinical Immunology, Hôpital Pitié Salpêtrière, 83 Boulevard de l'Hôpital, 75651 PARIS Cedex 13 – France. National Reference Center for Autoimmune Systemic Diseases, National Reference Center for Autoinflammatory Diseases and amyloidosis, European reference Network RITA (Immunodeficiency, Autoinflammatory and Autoimmune diseases), E-mail: david.saadoun@aphp.fr. Office : + 33 142178042, Fax : + 33 142178080, N° RPPS:10005176275

DEGREES AND PREVIOUS POSITION MD in 2007 Sorbonne University Paris VI; Gold medal of Internship in APHP, Paris; Master in immunopathology; PhD in Immunology in 2007, Sorbonne University Paris VI; Post-Doctoral position, 2008, New York, Weill Cornell University; Professor of Internal Medicine in 2012, at Sorbonne University, Hôpital Pitié Salpêtrière, Paris France.

CURRENT POSITION Professor of Internal Medicine & clinical Immunology Sorbonne University, Hôpital Pitié Salpêtrière, Paris France. Head of National Reference Center for Autoimmune Systemic Diseases, Head of National Reference Center for Autoinflammatory Diseases and amyloidosis. Director: INSERM U959 unit Immunopathology and Immunotherapies of autoimmune and inflammatory disorders (2009-Present). Laboratory of excellence (LabEX) TRANSIMMUNOM Phenomics in Autoimmune and Inflammatory Diseases. Recherche Hospitalo-universitaire en santé (RHU) Interleukin-2 therapy for autoimmune and inflammatory diseases.

PROFESSIONAL SOCIETIES Board of European Vasculitis Network (EUVAS). Board of the European Federation of Internal Medicine (EFIM), Board of the Research Study Group on Large vessel Vasculitis, Member of the European reference Network RITA (Immunodeficiency, Autoinflammatory and Autoimmune diseases), Président of the Groupe Français d'Etude des Maladies Inflammatoires Oculaires (GMIO).

PATENTS 2011 IL-2 based therapy (mai 2011), n° 11305269.02107. 2012 Multivariate Analysis for Biomarker Identification – Identification of classifiers of myositis and vasculitis, (2012) n°361600/D30194. Markers of autoimmune disease (2022) n° 10872023.

PUBLICATIONS 411 citations in PubMed, including 6 New England Journal of Medicine, 2 Journal of Clinical Investigation, 9 Circulation, 2 Gastroenterology, 2 Hepatology, 6 Blood, 2 JACI, 1 Gut , 1 JAMA Internal Med, 16 Ann Rheum Dis, 23 Arthritis Rheum, 7 Journal of hepatology.

CLINICAL RESEARCH

GCP certificate dated 09-OCT-2020

European study H2020 SAFE T (Biomarkers in vasculitis),

European study H2020 ImmunAID (MultiOmics in Inflammatory diseases)

PHRC national UVB, Uveitis in Behçet's,

PHRC national RUBI, Uveitis,

PHRC national ITAC, Induction therapy in severe Behçet's disease

PHRC national INTOReTAK : Infliximab and Tocilizumab in Refractory/relapsing TAKayasu arteritis

PHRC national CERIS, scleritis.

TRIBECA study, (ISS GSK, Rituximab plus Belimumab in Cryoglobulinemia vasculitis)

VASCUVALDIC studies (direct acting antiviral drug in HCV cryoglobulinemia vasculitis)

Relief STUDY: Apremilast in Behçet's disease (Phase III, Celgene)

Ustekinumab in Behçet's disease (Pilot study)

TRANSREG study: IL-2 low dose in autoimmune and inflammatory diseases

VASCU-IL2 study («IL-2 low dose in HCV cryoglobulinemia vasculitis »,

TransImmuno: MultiOmic approach in autoimmune diseases

ACT13480 SATURN study (anti-IL6 in Uveitis).

LUPIL, IL-2 low dose in Lupus

TOCITAKA, Tocilizumab in Takayasu

Tocilizumab in stroke of GCA

TOCIOAION Roche, Tocilizumab in optic neuropathy of GCA

PHRC national Syndrome d'Inflammation Oculaire Inexpliquée.

CL2-78989-012 study: efficacy and tolerance of Gevokizumab in GCA.

Medimmune study, anti ICOS in Sjogren's syndrome

GSK study, Rituximab plus Belimumab in Sjogren's syndrome

Chemocentryx study, Avocapan in AAV

Reovas study, Rituximab in EGPA

METOGIA study, Methotrexate vs Tocilizumab in GCA

Sanofi, Sarilumab in GCA

Sanofi, Sarilumab in PPR

PHRC national, IgIV in Sjogren's syndrome painful neuropathies

Abbvie, Jak inhibitors in GCA

PHRC national UVB, Tocilizumab vs adalimumab in Behçet's uveitis

PHRC national Paradise

B7 SARI : ISS Sanofi, Sarilumab in Behçet's

Jak inhibitors in SLE, Pfizer

Anti-CD40 in in Sjogren's syndrome, VelaBio

Rituximab plus Belimumab in Sjogren's syndrome (TRIBECA study) ISS GSK

B7931028 Pfizer "A phase 2b, double-blind, randomized, placebo-controlled, multicenter, dose-ranging study to evaluate the efficacy and safety profile of pf-06700841 in participants with active systemic lupus erythematosus "

ETAP PHRC Efficacy of Tocilizumab in Primary Sjögren's Syndrome.

START Consentium Européen "Molecular stratification of patients with giant cell arteritis to tailor glucocorticoid and tocilizumab therapy"

METOGIA CHU Dijon Bourgogne Méthotrexate versus tocilizumab pour le traitement de l'artérite à cellules géantes : étude multicentrique, randomisée, contrôlée

ITAC Assistance Publique - Hôpitaux de Paris Induction Therapy with Anti-TNF α vs Cyclophosphamide in severe Behçet disease

INTOReTAK Assistance Publique - Hôpitaux de Paris Multicentre, Randomized, Prospective Trial Evaluating the Efficacy and Safety of Infliximab to Tocilizumab in Refractory or Relapsing Takayasu Arteritis

MAINEPSAN Hospices Civils de Lyon Evaluate the Remission MAINTenance Using Extended Administration of Prednisone in Systemic Anti-neutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis.

MAINRITSEG Assistance Publique - Hôpitaux de Paris MAINTenance of remission with RITuximab versus azathioprine for patients with newly-diagnosed or relapsing Eosinophilic Granulomatosis with polyangiitis. A prospective, randomized, controlled, double-blind study: the MAINRITSEG trial.

COLCHIVAS Assistance Publique - Hôpitaux de Paris Intérêt de la colchicine pour prévenir les rechutes cutanées au cours de la vascularite à IgA de l'adulte

URBA Assistance Publique - Hôpitaux de Paris Multicenter, Randomized Study Evaluating the Value of Antitubercular Treatment During Recurrent Anterior Uveitis

USTEKINISU Centre Hospitalier Universitaire Dijon A Multicenter Phase 2 Single-arm Proof-of-concept Trial to Assess the Efficacy and Safety of Ustekinumab in Association With Prednisone for the Treatment of Non-infectious Severe Uveitis (NISU)

FAST Innotech International Assessment of the eFficacy, the Onset-of-Action and the Safety of Tot'héma® in Adults With Moderate Iron Deficiency Anaemia

CureCovid Genoscience A Study to Compare the Efficacy of GNS561 Versus Standard of Care in Patients With SARS-CoV-2 (COVID-19) Infection

Euro-COVIMID PHRC Prevalence, Seroconversion and Impact of COVID-19 in Autoimmune Diseases in Europe

PrepCov University Hospital, Toulouse Real-life Evaluation of the Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection in Patients Receiving Long-term Treatment for Systemic Lupus Erythematosus and/or Gougerot's Disease

CORIMUNO-19 "Cohort Multiple randomized controlled trials open label of immune modulatory drugs and other treatments in COVID-19 patients"

TATA Les Hôpitaux Universitaires de Strasbourg TArgeted Therapies in Auto-immune diseases

FOCUS : Adalimumab vs MTX in uveitis

ICE : Isatuximab in type 1 cryoglobulinemia

ACTOR : Corticoïdes plus anticoagulants vs corticoïdes dans thromboses du Behçet

UVB : Infliximab vs tocilizumab dans uvéite severe du Behçet

Coordinateur étude prospective Tocilizumab dans les aortites de GCA (ISS Fresenius)

Coordinateur de l'essai CRYOBI PHRC N (Obinutuzumab dans les vascularites cryoglobulinémiques)

Coordinateur de l'essai randomisé TAKA-SECU (secukinumab dans la maladie de Takayasu) sponsorisé par Novartis

Responsable scientifique de l'essai randomisé OLYMPE PHRC I (Evaluation du risque de troubles du rythme ventriculaires graves dans la sarcoïdose cardiaque par holter implantable)

Coordinateur de l'étude UVB-obs (idacio dans l'uvéite de la maladie de Behçet

Investigateur principal Essai randomisé URBA (antituberculat treatment during recurrent uveitis) : PHRC I

Investigateur principal Essai USTEKINISU (ustekinumab with prednisone in severe uveitis) : PHRCI

Investigateur principal Essai JACKUVEITE (baricitinib in uveitis) : PHRCI

Investigateur principal Essai randomisé CIRIS (cyclophosphamide vs infliximab in refractory scleritis) : HCL

Investigateur principal Essai randomisé GCAPTAIN (secukinumab in giant cell arteritis) : NOVARTIS

Investigateur principal Essai randomisé TOGIAC (Tocilizumab with IV-steroids in giant cell arteritis) : APHP

Investigateur principal Essai randomisé TOCIAION (Tocilizumab with steroids in giant cell arteritis with cerebro-vascular involvement) : CHNO 15-20

Investigateur principal Essai randomisé ALE.F02.03 (ALE.F02 in Antibody-Associated Vasculitis with Rapidly Progressive Glomerulonephritis) : MEDPACE

Investigateur principal Essai M23-699 (upadacitinib in moderate-severe active Systemic Lupus Erythematosus) : ABBVIE

Investigateur principal Essai randomisé ACT16618 (SAR441344 (anti CD40l) vs placebo in primary sjögren syndrom) : SANOFI

Investigateur principal Essai randomisé NEPTUNUS (lanalumab vs Placebo in active sjögren syndrom) : NOVARTIS